COVID-19 has dominated all aspects of American and international life over the past months. As the scope of the disease becomes more apparent by the day, we have begun to monitor the impact that COVID-19 has had on prescription drug prices, and unsurprisingly, there’s been volatility. To facilitate broader investigation into the impact COVID-19, we wanted to share within the public domain the list of national drug codes (NDCs) that included active ingredients currently being investigated in conjunction with COVID-19 according to ClinicalTrials.gov. This new tool will give users the ability to better track prices of drugs that are being evaluated as potential treatments options. Here’s how we did it, and how you can use it.
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw more price increases than decreases this past month. Also, for the second month in a row, we saw an increase in annualized spending based on typical utilization trends. It is becoming clear that the generic marketplace is not providing the deflation and efficiency that we have become accustomed to in recent years. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart.
With most of our generic drugs made in China and India, concerns about drug shortages are naturally rising amid the COVID-19 pandemic. Unfortunately, no amount of data analysis can systematically pinpoint which drugs are at highest risk of shortage. That’s because information on where the active pharmaceutical ingredients (APIs) in our drugs are made is kept hidden from public view. We must place our trust in the FDA (who clearly has this information) to do everything in its power to maintain ample supply of critical drugs in this country. But the FDA is not alone in its efforts. All across this country, we have been humbled to witness the tireless efforts of researchers and members of the media who are trying to piece together this drug supply chain puzzle to help identify where potential risks and weak points may lie. We were motivated to help assist these people in their noble efforts. So we wondered, could we use public drug pricing data as a “flashlight” that could help guide the efforts of researchers wandering through the dark and vast interconnectedness of the drug supply chain in hopes of finding information that can help Americans through this crisis? After working through and tossing out many ideas, we settled on two dashboards: A complete rebuild of our drugmaker market share dashboard, and a new dashboard that identifies drugs experiencing abnormal price increases. This report walks through how to use these new tools, and provides warnings on how to use, and how not to use these tools.
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw more price increases than decreases this past month, and for the first time in eight months, an increase in annualized spending based on typical utilization trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart.
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw less price increases than decreases this past month, and an overall decrease in annualized spending based on typical utilization trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart. Additionally, check out the interesting spike in hydrocodone-acetaminophen prices, which occurred just weeks after the major opioid lawsuit settlements.
On December 19, 2019, CMS released its highly-anticipated 2018 Medicare Part D spending data. Besides a few tweets and one article on the release, this very material event (at least for drug pricing nerds) apparently got lost in the year-end, impeachment-spiked, eggnog-soaked holiday daze. We stumbled upon this data in early January and immediately set out to study it and tell its story, and boy, there's a lot of story to tell.
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw more price increases this past month, but an overall decrease in annualized spending based on typical utilization trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart. Happy New Year.
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw less price increases this past month, and an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates on the latest generic drug price changes, plus an updated NADAC Packed Bubble Chart.
It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, but an overall decrease in annualized spending. As always, the details matter, and we’re here to provide them for you. For those that have followed previous 46brooklyn reports, there are several familiar drugs that experienced significant pricing movement this past month, so this piece will be a good trip down memory lane. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.
